Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTI: Intra-arterial Bevacizumab for Radiation Necrosis
NCT02819479Phase 2Completed
- Sponsor
- Norton Healthcare
- Start
- Nov 2016
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in radiation necrosis (RN), sponsored by Norton Healthcare. Primary endpoint: Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) at 12 months. Started Nov 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
radiation necrosis (RN)
Beyond the preview
Go deeper on NCT02819479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819479.